JP2010540519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540519A5 JP2010540519A5 JP2010526924A JP2010526924A JP2010540519A5 JP 2010540519 A5 JP2010540519 A5 JP 2010540519A5 JP 2010526924 A JP2010526924 A JP 2010526924A JP 2010526924 A JP2010526924 A JP 2010526924A JP 2010540519 A5 JP2010540519 A5 JP 2010540519A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- drug
- dose
- package
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 23
- 229960000265 cromoglicic acid Drugs 0.000 claims description 11
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 11
- 210000003630 histaminocyte Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004958 ketotifen Drugs 0.000 claims description 4
- 229960003630 ketotifen fumarate Drugs 0.000 claims description 4
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims description 4
- 229960004398 nedocromil Drugs 0.000 claims description 4
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 4
- 229960002259 nedocromil sodium Drugs 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000281 trometamol Drugs 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96040807P | 2007-09-28 | 2007-09-28 | |
| US60/960,408 | 2007-09-28 | ||
| PCT/US2008/011026 WO2009045291A2 (en) | 2007-09-28 | 2008-09-24 | Mast cell stabilizers in the treatment of obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540519A JP2010540519A (ja) | 2010-12-24 |
| JP2010540519A5 true JP2010540519A5 (OSRAM) | 2012-11-08 |
| JP5460600B2 JP5460600B2 (ja) | 2014-04-02 |
Family
ID=40523802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526924A Active JP5460600B2 (ja) | 2007-09-28 | 2008-09-24 | 肥満症治療における肥満細胞安定化薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8445435B2 (OSRAM) |
| EP (1) | EP2205243A4 (OSRAM) |
| JP (1) | JP5460600B2 (OSRAM) |
| CN (1) | CN101808642B (OSRAM) |
| WO (1) | WO2009045291A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445437B2 (en) | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| CA2766157A1 (en) | 2009-06-25 | 2010-12-29 | Hua Gong | Methods for diagnosing irritable bowel syndrome |
| CN102204871A (zh) * | 2011-06-01 | 2011-10-05 | 王青 | 一种减肥用组合物 |
| CN102846679A (zh) * | 2012-08-14 | 2013-01-02 | 王青 | 一种具有减肥作用的组合物 |
| CA2938996A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the treatment of lung diseases with mast cell stabilizers |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634699A (en) * | 1983-11-30 | 1987-01-06 | Burroughs Wellcome Co. | Branched chain phenothiazine |
| US4923892A (en) * | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) * | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| CA2161777A1 (en) * | 1993-05-10 | 1994-11-24 | Nancy M. Gray | Methods and compositions using optically pure (+)-zileuton |
| US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6225327B1 (en) | 1996-04-18 | 2001-05-01 | Alcon Laboratories, Inc. | Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications |
| US6207684B1 (en) * | 1997-06-09 | 2001-03-27 | Bridge Pharma, Inc. | Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use |
| KR20010021625A (ko) * | 1997-07-09 | 2001-03-15 | 추후보정 | 개선된 남성발기 기능장애 치료방법 및 그 조성물 |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6777429B1 (en) * | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
| US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20040115290A1 (en) * | 2001-06-20 | 2004-06-17 | Tripp Matthew L. | Modulation of inflammation by hops fractions and derivatives |
| US20040259952A1 (en) * | 2001-11-29 | 2004-12-23 | Richat Abbas | Formulations for oral administration of cromolyn sodium |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7271266B2 (en) * | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2006122069A2 (en) * | 2005-05-09 | 2006-11-16 | Azur Pharma | Formulations of mast cell stabilizing agents for delivery to the colon |
| EP2409973A1 (en) * | 2006-02-21 | 2012-01-25 | Critical Therapeutics, Inc. | New crystal form and pharmaceutical compositions of (+)-R-zileuton |
| US8445437B2 (en) | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
-
2008
- 2008-09-24 WO PCT/US2008/011026 patent/WO2009045291A2/en not_active Ceased
- 2008-09-24 US US12/232,789 patent/US8445435B2/en active Active
- 2008-09-24 CN CN200880108966XA patent/CN101808642B/zh not_active Expired - Fee Related
- 2008-09-24 JP JP2010526924A patent/JP5460600B2/ja active Active
- 2008-09-24 EP EP08835091A patent/EP2205243A4/en not_active Withdrawn
-
2013
- 2013-04-15 US US13/863,113 patent/US8785383B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540519A5 (OSRAM) | ||
| JP6391071B2 (ja) | シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤 | |
| US20130224151A1 (en) | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | |
| JP2015526458A5 (OSRAM) | ||
| JP2004519469A5 (OSRAM) | ||
| RU2011139643A (ru) | Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты | |
| WO2014018571A2 (en) | Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders | |
| BRPI0912607A2 (pt) | medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete | |
| JP2007530493A5 (OSRAM) | ||
| JP2006518731A5 (OSRAM) | ||
| JP2014508758A5 (OSRAM) | ||
| JP2008510758A5 (OSRAM) | ||
| JP2010513250A5 (OSRAM) | ||
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| US10682343B2 (en) | Snoring treatment | |
| EP1938814A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| JP2009506043A5 (OSRAM) | ||
| US20060246131A1 (en) | Use of metformin to counteract weight gain associated with psychotropic medications | |
| CN101056641A (zh) | 治疗潮红的s－米氮平 | |
| WO2004017973A1 (ja) | 統合失調症治療剤 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| RU2006110550A (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| EP3711756A1 (en) | Use of carbamate compound for preventing, alleviating or treating myotonia | |
| RU2414895C2 (ru) | Способ лечения поражения печени у больных лепрой |